Mechanism of factor VIIa-dependent coagulation in hemophilia blood.

The ability of factor VIIa to initiate thrombin generation and clot formation in blood from healthy donors, blood from patients with hemophilia A, and in anti-factor IX antibody-induced ("acquired") hemophilia B blood was investigated. In normal blood, both factor VIIa-tissue factor (TF) complex and factor VIIa alone initiated thrombin generation. The efficiency of factor VIIa was about 0.0001 that of the factor VIIa-TF complex. In congenital hemophilia A blood and "acquired" hemophilia B blood in vitro, addition of 10 to 50 nM factor VIIa (pharmacologic concentrations) corrected the clotting time at all TF concentrations tested (0-100 pM) but had little effect on thrombin generation. Fibrinopeptide release and insoluble clot formation were only marginally influenced by addition of factor VIIa. TF alone had a more pronounced effect on thrombin generation; an increase in TF from 0 to 100 pM increased the maximum thrombin level in "acquired" hemophilia B blood from 120 to 480 nM. Platelet activation was considerably enhanced by addition of factor VIIa to both hemophilia A blood and "acquired" hemophilia B blood. Thus, pharmacologic concentrations of factor VIIa cannot restore normal thrombin generation in hemophilia A and hemophilia B blood in vitro. The efficacy of factor VIIa (10-50 nM) in hemophilia blood is dependent on TF.

[1]  P. Wolf,et al.  A concentrate of human antihaemophilic factor; its use in six cases of haemophilia. , 1957, Lancet.

[2]  D. Hammond,et al.  Evaluation of a new concentrate for the treatment of factor IX deficiency. , 1969, The New England journal of medicine.

[3]  J. Mustard,et al.  Preparation of Suspensions of Washed Platelets from Humans , 1972, British journal of haematology.

[4]  Ş. Ozsoylu,et al.  Acquired factor IX deficiency. A report of two cases. , 1973, Acta haematologica.

[5]  C. Kasper,et al.  Detection of factor VIII inhibitors with the partial thromboplastin time. , 1977, Blood.

[6]  B. Hopkin.  Frapper fort ou doucement:A Gramnegative dilemma. , 1978 .

[7]  K. Mann,et al.  Isolation of functional human coagulation factor V by using a hybridoma antibody. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Rapaport,et al.  A simplified procedure for purification of human prothrombin, factor IX and factor X. , 1981, Preparative biochemistry.

[9]  M. Ragni,et al.  Factor VII deficiency , 1981, American journal of hematology.

[10]  C. Fulcher,et al.  Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W. Kisiel,et al.  Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. , 1983, The Journal of clinical investigation.

[12]  R. Colman,et al.  Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants. , 1983, The Journal of clinical investigation.

[13]  S. Schulman,et al.  Hepatitis, epidemiology and liver function in hemophiliacs in Sweden. , 2009, Acta medica Scandinavica.

[14]  M. Griffith,et al.  Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. , 1985, The Journal of biological chemistry.

[15]  E. Berntorp,et al.  Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Blombäck,et al.  SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY , 1988, The Lancet.

[17]  P. Saidi,et al.  Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. , 1990, Seminars in hematology.

[18]  Y Komiyama,et al.  Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. , 1990, Biochemistry.

[19]  P. Mannucci,et al.  Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. , 1990, The New England journal of medicine.

[20]  H. Breddin.  Pathophysiology of thromboembolism and its modulation by low molecular weight heparins. , 1993, Seminars in thrombosis and hemostasis.

[21]  A. Thompson.  Factor IX concentrates for clinical use. , 1993, Seminars in thrombosis and hemostasis.

[22]  K. Mann,et al.  Extrinsic pathway proteolytic activity. , 1993, Methods in enzymology.

[23]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. I. An empirical study. , 1994, The Journal of biological chemistry.

[24]  L. Hoyer,et al.  Hemophilia A. , 2020, The New England journal of medicine.

[25]  E. Gordon,et al.  A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.

[26]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. II. A mathematical simulation. , 1994, Journal of Biological Chemistry.

[27]  L. Hoyer.  Medical progress : hemophilia A , 1994 .

[28]  P. Reitsma,et al.  Homozygosity for a Novel Missense Mutation in the Prothrombin Gene Causing a Severe Bleeding Disorder , 1994, Thrombosis and Haemostasis.

[29]  K. Mann,et al.  Blood clotting in minimally altered whole blood. , 1996, Blood.

[30]  B. Nielsen,et al.  Recombinant Factor IX , 1997, Thrombosis and Haemostasis.

[31]  J. Oliver,et al.  Platelet activity of high‐dose factor VIIa is independent of tissue factor , 1997, British journal of haematology.

[32]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[33]  K. Mann,et al.  Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases* , 1997, The Journal of Biological Chemistry.

[34]  Kenneth G. Mann,et al.  Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.

[35]  U. Hedner.  Recombinant activated factor VII as a universal haemostatic agent. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[36]  K. Mann,et al.  Blood coagulation in hemophilia A and hemophilia C. , 1998, Blood.

[37]  M. Udvardy.  [New possibilities in the management of hemorrhagic diathesis caused by factor deficiency and thrombocytopenia: recombinant active factor VII concentrate]. , 1998, Orvosi hetilap.

[38]  P. Mannucci,et al.  A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[39]  H. Roberts,et al.  Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[40]  M. Levi,et al.  Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. , 1998, The Netherlands journal of medicine.

[41]  A D Shapiro,et al.  Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.

[42]  Shapiro,et al.  A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors , 1998 .

[43]  J. Gill,et al.  Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.

[44]  Kenneth G. Mann,et al.  An Integrated Study of Fibrinogen during Blood Coagulation* , 1999, The Journal of Biological Chemistry.

[45]  M. Manco-Johnson,et al.  Evidence for Antiphospholipid Antibodies in Hemophilic Children with Factor VIII Inhibitors , 1999, Thrombosis and Haemostasis.

[46]  O. Schiraldi,et al.  Treatment with recombinant activated factor VII in a patient with hemophilia A and an inhibitor: advantages of administration by continuous infusion over bolus intermittent injections. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[47]  C. Rothschild,et al.  Incidence of Factor IX Inhibitor Development in Severe Haemophilia B Patients Treated with only one Brand of High Purity Plasma Derived Factor IX Concentrate , 1999, Thrombosis and Haemostasis.

[48]  R. Santoro,et al.  Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[49]  T. VandenDriessche,et al.  Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Mann,et al.  Novel, Bedside, Tissue Factor–Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy , 2000, Circulation.

[51]  Shapiro,et al.  A Multicenter Study of Recombinant Factor VI11 (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A , 2000 .

[52]  K. Bauer,et al.  Recombinant Factor VIIa for the Treatment of Congenital Factor VII Deficiency , 2000, Seminars in thrombosis and hemostasis.

[53]  A. Mureşan,et al.  Recombinant factor VIIa treatment of bleeding associated with acute renal failure. , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[54]  K. Mann,et al.  Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. , 2000, Blood.

[55]  A D Shapiro,et al.  Recombinant Factor VIIa in the Treatment of Bleeding in Hemophilic Children with Inhibitors , 2000, Seminars in thrombosis and hemostasis.

[56]  D. Bernstein,et al.  Effectiveness of the Recombinant Factor VIIa in Patients with the Coagulopathy of Advanced Child's B and C Cirrhosis , 2000, Seminars in thrombosis and hemostasis.

[57]  J. Ingerslev,et al.  Efficacy and Safety of Recombinant Factor VIIa in the Prophylaxis of Bleeding in Various Surgical Procedures in Hemophilic Patients with Factor VIII and Factor IX Inhibitors , 2000, Seminars in thrombosis and hemostasis.

[58]  S. Schulman.  Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness , 2000, Seminars in thrombosis and hemostasis.

[59]  C. Négrier,et al.  The Treatment of Bleeding in Hemophilic Patients with Inhibitors with Recombinant Factor VIIa , 2000, Seminars in thrombosis and hemostasis.

[60]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[61]  R. d'Oiron,et al.  Recombinant activated factor VII (NovoSeven®) treatment of platelet‐related bleeding disorders , 2000 .

[62]  E. Berntorp.  Recombinant FVIIa in the Treatment of Warfarin Bleeding , 2000, Seminars in thrombosis and hemostasis.

[63]  K. Mann,et al.  Platelets and Phospholipids in Tissue Factor-initiated Thrombin Generation , 2001, Thrombosis and Haemostasis.

[64]  V. Nielsen,et al.  Considerations for the hemophiliac patient with inhibitors to factor VIII. , 2001, Anesthesia and analgesia.

[65]  E. Briët,et al.  Successful treatment with recombinant factor VIIa of therapy‐resistant severe bleeding in a patient with acquired von Willebrand disease , 2001, American journal of hematology.

[66]  K. High.  Gene therapy: a 2001 perspective , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[67]  R. Holman,et al.  Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States , 2001, American journal of hematology.

[68]  R. Herzog,et al.  Posttranslational modifications of recombinant myotube-synthesized human factor IX. , 2001, Blood.

[69]  Joseph Loscalzo,et al.  Thrombosis and Hemorrhage , 2002 .